Xspray Pharma AB (publ)
OM:XSPRAY Stock Report
Xspray Pharma Balance Sheet Health
Financial Health criteria checks 6/6 Xspray Pharma has a total shareholder equity of SEK585.6M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK667.7M and SEK82.1M respectively.
Key information Interest coverage ratio n/a Cash SEK 74.76m Equity SEK 585.59m Total liabilities SEK 82.10m Total assets SEK 667.70m
Recent financial health updates
Show all updates Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025 Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million. Nov 07
Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025 Oct 22
Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025 Oct 21
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission Sep 19
New major risk - Financial position Aug 09
Director recently bought kr4.8m worth of stock Jul 31
Price target decreased by 24% to kr91.50 Jul 31
New major risk - Share price stability Jul 29
Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose Jul 10
Director recently bought kr143k worth of stock Jul 05
Now 32% undervalued Jul 01
Now 23% undervalued Jun 17
Price target decreased by 11% to kr107 Jun 16
New minor risk - Share price stability Jun 12
Insufficient new directors Jun 02
Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib May 24
Director recently bought kr504k worth of stock May 21
Chief Executive Officer recently sold kr75k worth of stock May 08
Chairman exercised options to buy kr24m worth of stock. May 05
Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025 Mar 28
New minor risk - Share price stability Mar 21
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully Feb 25 Xspray Pharma AB (publ) to Report Q3, 2024 Results on Nov 06, 2024
New major risk - Revenue and earnings growth Feb 16
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA Feb 13 Xspray Pharma AB (publ) Appoints Kerstin Hasselgren as Head of IR
Director recently bought kr2.1m worth of stock Jan 21
Independent Director exercised options to buy kr97k worth of stock. Dec 03
Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage Nov 22
Director recently bought kr5.0m worth of stock Nov 16
Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies Nov 10 Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024
New major risk - Financial position Sep 20
Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer Sep 16 Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch Sep 12
Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024 Aug 03
Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA Jul 12
Price target decreased by 21% to kr106 May 08
Chief Executive Officer recently sold kr2.2m worth of stock Mar 15
Director recently bought kr135k worth of stock Mar 04 Xspray Pharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 29, 2023
Director recently bought kr2.6m worth of stock Dec 02
Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia Dec 01
Forecast to breakeven in 2024 Nov 16 Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023
Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer Jun 16
Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors May 20
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate May 11
Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023 May 07
Price target decreased to kr116 Apr 27
Forecast to breakeven in 2024 Apr 27
Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022 Feb 19
Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022 Feb 08
We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth Feb 01
Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™ Jan 14
Price target decreased to kr116 Nov 26
No longer forecast to breakeven Nov 24
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate Oct 26
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate Jun 20
Independent Chairman of the Board Michael Jensen has left the company May 26
We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely Mar 19
New 90-day low: kr113 Mar 06
Xspray Pharma AB (publ) Announces Nomination Committee for the AGM 2021 Feb 18
Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares? Feb 12
New 90-day low: kr114 Feb 06
Chief Executive Officer exercised options and sold kr3.6m worth of stock Jan 28
Xspray Pharmas study with modified formulation of HyNap-Dasa has now started Jan 24
New 90-day low: kr127 Jan 18
Xspray Pharma Announces Results from Additional Bioequivalence Study Jan 15
Xspray Pharma’S Hynap-Nilo Receives Fda Orphan Drug Designation for the Treatment of Chronic Myeloid Leukemia Dec 30
New 90-day high: kr196 Dec 30
Xspray Pharma AB (publ) Decides to Await the Result of Two Ongoing Clinical Studies Before Submitting Its Anda Application Dec 13
Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation Dec 04 Xspray Pharma AB (publ) to Report Q1, 2021 Results on May 06, 2021
Independent Chairman of the Board recently sold kr1.4m worth of stock Oct 02
Xspray Pharma AB Announces Positive Preliminary Results from the Study for Its Lead Product Candidate HyNap-Dasa Sep 26
Michael Wolff Jensen Will Not Stand for Re-Election as Chairman of Xspray Pharma AB Sep 22
Independent Director recently bought kr151k worth of stock Aug 20
Financial Position Analysis
Short Term Liabilities: XSPRAY's short term assets (SEK101.5M) exceed its short term liabilities (SEK53.5M).
Long Term Liabilities: XSPRAY's short term assets (SEK101.5M) exceed its long term liabilities (SEK28.6M).
Debt to Equity History and Analysis
Debt Level: XSPRAY is debt free.
Reducing Debt: XSPRAY has not had any debt for past 5 years.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XSPRAY has sufficient cash runway for 4 months based on last reported free cash flow , but has since raised additional capital.
Forecast Cash Runway: XSPRAY is forecast to have sufficient cash runway for 6 months based on free cash flow estimates , but has since raised additional capital.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
